Developer docs
API playgroundTry for free, no card

Search company profiles

Croma Pharma

Full company profile

uuid003f16a

Namestring
Croma Pharma
Legal namestring
Croma-Pharma GmbH
Websiteurl
croma.at
Company typeenum
Private
Founded yearint
1976
Descriptiontext

Croma-Pharma GmbH is an Austrian family-owned pharmaceutical company founded in 1976 and headquartered in Leobendorf, Austria, operating in the minimally invasive aesthetics and orthobiologics markets. The company manufactures premium hyaluronic acid syringes and has produced more than 110 million units over its history, with current operations spanning more than 80 countries and 251-500 employees. Its core product portfolio covers the full minimally invasive aesthetics value chain: hyaluronic acid fillers (including the FDA-approved Obagi saypha ChIQ for cheek augmentation under the MACRO Core Technology platform), botulinum toxin, skin boosters (PhilArt), PDO threads, autologous PRP/Fluid-PRF systems, and a consumer skincare line launched in 2026. The company also operates the Clinicore digital SaaS platform for aesthetic clinic management via a joint venture with Medfile, and recently reacquired Synocrom to re-enter the orthopaedics (knee osteoarthritis) segment.

Revenue is generated through five primary streams: one-time B2B product sales to healthcare professionals and aesthetic clinics via a dedicated webshop (cromapharma.shop) and direct sales force; consumer skincare product sales; sales of MDR-certified orthobiologic devices to orthopaedic practitioners; subscription revenue from the Clinicore SaaS platform; and licensing/co-development royalties from strategic partners such as Waldencast/Obagi Medical. Go-to-market blends enterprise field sales with channel partnerships, including the Waldencast/Obagi relationship for US distribution and the ALOHA Program partnerships with US clinic networks (Schweiger Dermatology, ProMD, Aesthetic Record, Moxie, VIO Med Spa, Next Health, It's a Secret Med Spa) to generate real-world clinical evidence. End customers span healthcare professionals and aesthetic practitioners (primary), aesthetic clinics and med spas, orthopaedic specialists, and end consumers. The company is privately held, family-owned, Ecovadis Gold-rated for sustainability, and expanding aggressively across geographies, verticals, and product lines in 2026.

Short descriptiontext

Croma-Pharma GmbH is an Austrian family-owned pharmaceutical company founded in 1976 that manufactures premium hyaluronic acid syringes and a comprehensive minimally invasive aesthetics portfolio (fillers, toxins, skin boosters, PDO threads, PRP), serving healthcare professionals, aesthetic clinics, and orthopaedic specialists across more than 80 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersLeobendorf, Austria
HQ citystring
Leobendorf
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hyaluronic acid injectables, aesthetic medicine products, dermal filler manufacturing, minimally invasive aesthetics, orthobiologic medical devices
Industry3 codes
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Perfumes, Cosmetics & Other Toilet Preparations2844
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Medical Aesthetics (Hyaluronic Acid Injectables)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Aesthetics Product Portfolio Sales
TypeOne Time License
Description

Sales of comprehensive minimally invasive aesthetics portfolio including hyaluronic acid fillers, botulinum toxin, skin boosters, PDO threads, autologous PRP/Fluid-PRF, and skincare products to healthcare professionals and aesthetic clinics globally

cromapharma.com
2Skincare Consumer Products
TypeOne Time License
Description

Consumer-facing Croma Skincare line launched in 2026, including THE GLOW (20% vitamin C serum), THE EVERYDAY, THE SHIELD, and THE SUNKISSED products

cromapharma.com
3Orthobiologics/Medical Devices
TypeOne Time License
Description

Sales of hyaluronic acid-based medical devices for orthopaedics including Synocrom for knee osteoarthritis treatment, MDR-certified and available in EU and Switzerland

aijourn.com
4Clinicore SaaS Platform
TypeSubscription Recurring
Description

Digital platform subscription revenue from Clinicore, an AI-driven SaaS platform for aesthetic clinic management including automated documentation and onboarding tools

via.ritzau.dk
5Licensing and Development Partnerships
TypeLicensing Royalties
Description

Technology licensing and co-development partnerships including Waldencast/Obagi Medical for injectable product development utilizing MACRO Core Technology

stocktitan.net
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1cromacare
Description

Croma's global framework for all educational activities in aesthetic medicine, empowering healthcare professionals.

cromapharma.com
+2 more records
Core offering1 text field

Croma-Pharma manufactures and distributes a comprehensive minimally invasive aesthetics portfolio including hyaluronic acid (HA) dermal fillers, botulinum toxin, skin boosters, PDO threads, and autologous PRP/Fluid-PRF treatments, plus an MDR-certified orthobiologic (Synocrom) for knee osteoarthritis. The company sells its products primarily to healthcare professionals and aesthetic clinics through direct B2B sales and a dedicated webshop (cromapharma.shop), and operates the Clinicore AI-driven SaaS platform for aesthetic clinic management alongside a consumer skincare line.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 110 million hyaluronic acid syringes produced since 1976
+1 more record
Product overview1 text field

Croma-Pharma is a global player in the minimally invasive aesthetics market and leading European manufacturer of hyaluronic acid syringes. The company offers a comprehensive portfolio of aesthetic products including Hyaluronic Acid Fillers, Botulinum Toxin, Skin Boosters (PhilArt), PDO Threads, and Autologous PRP/Fluid-PRP treatments. The portfolio extends to everyday skincare with the Croma Skincare line (THE GLOW, THE EVERYDAY, THE SHIELD, THE SUNKISSED), and has recently expanded into orthopaedics with Synocrom. Beyond products, Croma provides digital infrastructure through the Clinicore SaaS platform and supports healthcare professionals via the cromacare education platform. Products are distributed through the B2B Onlineshop across more than 80 countries.

Product and service9 records
1Hyaluronic Acid Filler
CategoryHyaluronic Acid Dermal Fillers
Description

Premium hyaluronic acid injectable dermal fillers for aesthetic treatments, including the Saypha filler range, manufactured by Croma-Pharma as a leading European producer of HA syringes. Sold to aesthetic physicians, dermatologists, and healthcare professionals globally.

2Botulinum Toxin
CategoryBotulinum Toxin Injectables
Description

Neurotoxin-based injectable product for aesthetic treatments targeting dynamic wrinkles. Distributed to healthcare professionals and aesthetic clinics through B2B channels.

3Skin Booster (PhilArt)
CategorySkin Boosters / Biostimulatory Injectables
Description

Biostimulatory injectables, also known as skin boosters, designed to deliver deep skin hydration and improve skin quality. The PhilArt line is Croma-Pharma's biostimulatory injectable product for aesthetic practitioners.

4PDO Threads
CategoryThread Lifting Products
Description

Polydioxanone (PDO) thread-based aesthetic treatments for skin lifting and rejuvenation procedures, sold to aesthetic practitioners and clinics.

5Autologous PRP / Fluid-PRF
CategoryRegenerative Aesthetics / PRP Systems
Description

Platelet-rich plasma (PRP) and Fluid-PRF aesthetic treatment systems for skin regeneration procedures, sold to healthcare professionals performing regenerative aesthetic treatments.

6Croma Skincare Line (THE GLOW, THE EVERYDAY, THE SHIELD, THE SUNKISSED)
CategoryConsumer Skincare
Description

Consumer-facing everyday skincare line from Croma-Pharma including THE GLOW (20% vitamin C serum), THE EVERYDAY, THE SHIELD, and THE SUNKISSED, formulated with niacinamide, peptides, and plant stem cells. Vegan and dermatologically tested, bridging in-clinic aesthetic treatments with at-home skincare routines for end consumers.

7saypha ChIQ (Obagi saypha ChIQ)
CategoryHyaluronic Acid Dermal Fillers
Description

FDA-approved injectable hyaluronic acid gel filler for cheek augmentation and midface contour correction, utilizing Croma-Pharma's proprietary MACRO Core Technology. Developed in partnership with Obagi Medical (Waldencast plc) for the US market.

8Synocrom
CategoryOrthobiologics / Medical Devices
Description

MDR-certified, biologically derived hyaluronic acid product for treating knee osteoarthritis, with three decades of clinical use. Sold to orthopaedic specialists and healthcare professionals in the EU and Switzerland.

9Clinicore Platform
CategoryHealthcare SaaS / Clinic Management Software
Description

Premium digital SaaS platform for aesthetic clinics incorporating AI-driven features for automated treatment documentation and intelligent onboarding tools. Developed in partnership with Medfile and sold to aesthetic clinic operators.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-15
Description

Partnership for development and distribution of Obagi saypha ChIQ injectable hyaluronic acid gel filler approved by FDA for cheek augmentation and midface contour correction. Product utilizes Croma's proprietary MACRO Core Technology, expanding Obagi's injectable portfolio in the US market.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-26
Description

Strategic joint venture to accelerate Clinicore platform development. Partnership integrates AI-driven features including automated treatment documentation and intelligent onboarding tools into Croma's premium digital SaaS platform for aesthetic clinics.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-03-19
Description

ALOHA Program collaboration to conduct real-world clinical evaluation of Obagi saypha MagIQ hyaluronic acid dermal filler across ProMD's 17 multi-state practice locations, collecting standardized data on clinical efficacy and patient experience.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-02-27
Description

ALOHA Program key partner to conduct Phase 4 clinical study and real-world evaluation of Obagi saypha MagIQ injectable product across Schweiger's national network of practices, with initial activities beginning early 2026.

5It's a Secret Med Spa
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-02-25
Description

ALOHA Program collaboration to evaluate Obagi saypha MagIQ across 15 med spa locations using structured data capture and clinical protocols, translating FDA pivotal trial data into everyday premium med spa practice.

stocktitan.net
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-02-17
Description

ALOHA Program partnership leveraging Aesthetic Record's EMR, charting, and analytics platform across network of over 9,000 aesthetic clinics to generate real-world evidence for Obagi saypha MagIQ injectable.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-02-05
Description

ALOHA Program strategic partner using software, coaching, and operational tools to collect standardized data on filler integration into scalable aesthetic workflows across Moxie's supported med spa network.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-01-30
Description

ALOHA Program launch partner conducting real-world clinical evaluations of Obagi saypha MagIQ across VIO's national network of med spa locations, generating evidence on performance and patient outcomes.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-01-28
Description

ALOHA Program partnership for structured multi-site assessment of Obagi saypha MagIQ filler across Next Health's wellness and longevity centers, leveraging integration of injectables with holistic protocols.

10Novaestiq Corp.
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-07-23
Description

Novaestiq Corp. acquired by Waldencast plc as part of Croma's expansion strategy, including launch of Saypha injectables in US under Obagi Medical brand.

prnewswire.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Owns the Juvéderm HA filler franchise and Botox—the global category leaders in aesthetic injectables. A large public incumbent whose scale and R&D budget dwarf Croma's; directly competes across Croma's core injectable categories.

TypeDirect peer
Description

Global dermatology and aesthetics leader with the Restylane HA filler portfolio, Sculptra biostimulator, and Dysport (botulinum toxin). Most direct competitor to Croma's minimally invasive aesthetics portfolio, especially in HA fillers and skin boosters.

TypeDirect peer
Description

Swiss manufacturer of HA-based dermal fillers (Teosyal range) and skincare. A direct European HA-filler peer with a comparable private, specialty-manufacturer profile and overlapping target customer (aesthetic practitioners).

4SkinCeuticals (L'Oréal Dermatological Beauty)
TypeBroad incumbent
Description

Medical-grade skincare brand owned by L'Oréal. Comparable to Croma Skincare's positioning at the intersection of clinical aesthetics and consumer skincare, and a benchmark for Croma's consumer channel ambitions.

5Evolus
TypeEmerging player
Description

US aesthetics company focused on botulinum toxin (Jeuveau). A focused competitor in the same minimally invasive aesthetics category as Croma's botulinum toxin product.

TypeDirect peer
Description

Private German company offering Belotero HA fillers, Xeomin botulinum toxin, and Ultherapy. Closest peer to Croma: a private, European-rooted, mid-sized aesthetics player competing across overlapping injectable categories.

TypeRegional player
Description

Korean aesthetics and medical aesthetics player with botulinum toxin (Botulax) and HA fillers. Comparable product portfolio to Croma's, primarily serving APAC but increasingly expanding globally.

TypeDirect peer
Description

European aesthetics company (acquired by Huadong Medicine) with Ellansé biostimulator and HA fillers. A close comparable in size and business model before acquisition—mid-sized European aesthetics player serving the same HCP customer base.

9Revance Therapeutics
TypeEmerging player
Description

US aesthetics company with the RHA Collection of HA fillers and Daxxify (long-acting botulinum toxin). Comparable as a focused injectable aesthetics specialist targeting similar HCP customers.

TypeDirect peer
Description

Swiss pharma company offering HA-based products (e.g., Profhilo bio-remodelling, Sinovial for joint care). Directly comparable to Croma across both aesthetic injectables and orthobiologics (overlapping with Synocrom).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Croma Pharma

Medical Aesthetics (Hyaluronic Acid Injectables)croma.at

Croma-Pharma GmbH is an Austrian family-owned pharmaceutical company founded in 1976 that manufactures premium hyaluronic acid syringes and a comprehensive minimally invasive aesthetics portfolio (fillers, toxins, skin boosters, PDO threads, PRP), serving healthcare professionals, aesthetic clinics, and orthopaedic specialists across more than 80 countries.

What Croma Pharma does

Croma-Pharma GmbH is an Austrian family-owned pharmaceutical company founded in 1976 and headquartered in Leobendorf, Austria, operating in the minimally invasive aesthetics and orthobiologics markets. The company manufactures premium hyaluronic acid syringes and has produced more than 110 million units over its history, with current operations spanning more than 80 countries and 251-500 employees. Its core product portfolio covers the full minimally invasive aesthetics value chain: hyaluronic acid fillers (including the FDA-approved Obagi saypha ChIQ for cheek augmentation under the MACRO Core Technology platform), botulinum toxin, skin boosters (PhilArt), PDO threads, autologous PRP/Fluid-PRF systems, and a consumer skincare line launched in 2026. The company also operates the Clinicore digital SaaS platform for aesthetic clinic management via a joint venture with Medfile, and recently reacquired Synocrom to re-enter the orthopaedics (knee osteoarthritis) segment.

Revenue is generated through five primary streams: one-time B2B product sales to healthcare professionals and aesthetic clinics via a dedicated webshop (cromapharma.shop) and direct sales force; consumer skincare product sales; sales of MDR-certified orthobiologic devices to orthopaedic practitioners; subscription revenue from the Clinicore SaaS platform; and licensing/co-development royalties from strategic partners such as Waldencast/Obagi Medical. Go-to-market blends enterprise field sales with channel partnerships, including the Waldencast/Obagi relationship for US distribution and the ALOHA Program partnerships with US clinic networks (Schweiger Dermatology, ProMD, Aesthetic Record, Moxie, VIO Med Spa, Next Health, It's a Secret Med Spa) to generate real-world clinical evidence. End customers span healthcare professionals and aesthetic practitioners (primary), aesthetic clinics and med spas, orthopaedic specialists, and end consumers. The company is privately held, family-owned, Ecovadis Gold-rated for sustainability, and expanding aggressively across geographies, verticals, and product lines in 2026.

Croma Pharma firmographics

Firmographics
Name
Croma Pharma
Legal name
Croma-Pharma GmbH
Website
https://croma.at
Company type
Private
Founded year
1976
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Croma-Pharma GmbH is an Austrian family-owned pharmaceutical company founded in 1976 that manufactures premium hyaluronic acid syringes and a comprehensive minimally invasive aesthetics portfolio (fillers, toxins, skin boosters, PDO threads, PRP), serving healthcare professionals, aesthetic clinics, and orthopaedic specialists across more than 80 countries.
Ownership category
akta.pro rank

Croma Pharma industry classification

Industry
Product category
Medical Aesthetics (Hyaluronic Acid Injectables)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Surgical & Medical Instruments & Apparatus (3841), Perfumes, Cosmetics & Other Toilet Preparations (2844), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare

Keywords

  • Hyaluronic acid injectables
  • Aesthetic medicine products
  • Dermal filler manufacturing
  • Minimally invasive aesthetics
  • Orthobiologic medical devices

Where Croma Pharma is headquartered

Location

Headquarters

HQ city
Leobendorf
HQ country
Austria
HQ region
Europe

Offices1 record

Markets served

Croma Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Aesthetics Product Portfolio Sales: Sales of comprehensive minimally invasive aesthetics portfolio including hyaluronic acid fillers, botulinum toxin, skin boosters, PDO threads, autologous PRP/Fluid-PRF, and skincare products to healthcare professionals and aesthetic clinics globally
  2. Skincare Consumer Products: Consumer-facing Croma Skincare line launched in 2026, including THE GLOW (20% vitamin C serum), THE EVERYDAY, THE SHIELD, and THE SUNKISSED products
  3. Orthobiologics/Medical Devices: Sales of hyaluronic acid-based medical devices for orthopaedics including Synocrom for knee osteoarthritis treatment, MDR-certified and available in EU and Switzerland
  4. Clinicore SaaS Platform: Digital platform subscription revenue from Clinicore, an AI-driven SaaS platform for aesthetic clinic management including automated documentation and onboarding tools
  5. Licensing and Development Partnerships: Technology licensing and co-development partnerships including Waldencast/Obagi Medical for injectable product development utilizing MACRO Core Technology

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Croma Pharma product offering

Product offering

Core offering

Croma-Pharma manufactures and distributes a comprehensive minimally invasive aesthetics portfolio including hyaluronic acid (HA) dermal fillers, botulinum toxin, skin boosters, PDO threads, and autologous PRP/Fluid-PRF treatments, plus an MDR-certified orthobiologic (Synocrom) for knee osteoarthritis. The company sells its products primarily to healthcare professionals and aesthetic clinics through direct B2B sales and a dedicated webshop (cromapharma.shop), and operates the Clinicore AI-driven SaaS platform for aesthetic clinic management alongside a consumer skincare line.

Product overview

Croma-Pharma is a global player in the minimally invasive aesthetics market and leading European manufacturer of hyaluronic acid syringes. The company offers a comprehensive portfolio of aesthetic products including Hyaluronic Acid Fillers, Botulinum Toxin, Skin Boosters (PhilArt), PDO Threads, and Autologous PRP/Fluid-PRP treatments. The portfolio extends to everyday skincare with the Croma Skincare line (THE GLOW, THE EVERYDAY, THE SHIELD, THE SUNKISSED), and has recently expanded into orthopaedics with Synocrom. Beyond products, Croma provides digital infrastructure through the Clinicore SaaS platform and supports healthcare professionals via the cromacare education platform. Products are distributed through the B2B Onlineshop across more than 80 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • cromacare: Croma's global framework for all educational activities in aesthetic medicine, empowering healthcare professionals.
  • Clinicore
  • Croma Skincare

Products and services

  • Hyaluronic Acid Filler Premium hyaluronic acid injectable dermal fillers for aesthetic treatments, including the Saypha filler range, manufactured by Croma-Pharma as a leading European producer of HA syringes. Sold to aesthetic physicians, dermatologists, and healthcare professionals globally.
  • Botulinum Toxin Neurotoxin-based injectable product for aesthetic treatments targeting dynamic wrinkles. Distributed to healthcare professionals and aesthetic clinics through B2B channels.
  • Skin Booster (PhilArt) Biostimulatory injectables, also known as skin boosters, designed to deliver deep skin hydration and improve skin quality. The PhilArt line is Croma-Pharma's biostimulatory injectable product for aesthetic practitioners.
  • PDO Threads Polydioxanone (PDO) thread-based aesthetic treatments for skin lifting and rejuvenation procedures, sold to aesthetic practitioners and clinics.
  • Autologous PRP / Fluid-PRF Platelet-rich plasma (PRP) and Fluid-PRF aesthetic treatment systems for skin regeneration procedures, sold to healthcare professionals performing regenerative aesthetic treatments.
  • Croma Skincare Line (THE GLOW, THE EVERYDAY, THE SHIELD, THE SUNKISSED) Consumer-facing everyday skincare line from Croma-Pharma including THE GLOW (20% vitamin C serum), THE EVERYDAY, THE SHIELD, and THE SUNKISSED, formulated with niacinamide, peptides, and plant stem cells. Vegan and dermatologically tested, bridging in-clinic aesthetic treatments with at-home skincare routines for end consumers.
  • saypha ChIQ (Obagi saypha ChIQ) FDA-approved injectable hyaluronic acid gel filler for cheek augmentation and midface contour correction, utilizing Croma-Pharma's proprietary MACRO Core Technology. Developed in partnership with Obagi Medical (Waldencast plc) for the US market.
  • Synocrom MDR-certified, biologically derived hyaluronic acid product for treating knee osteoarthritis, with three decades of clinical use. Sold to orthopaedic specialists and healthcare professionals in the EU and Switzerland.
  • Clinicore Platform Premium digital SaaS platform for aesthetic clinics incorporating AI-driven features for automated treatment documentation and intelligent onboarding tools. Developed in partnership with Medfile and sold to aesthetic clinic operators.

Quantifiable outcome

  • Over 110 million hyaluronic acid syringes produced since 1976
  • +1 more outcomes

Companies that use Croma Pharma

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Croma Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Croma Pharma partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and flagship.

  • Waldencast plc / Obagi MedicalcoreStrategic or Co-development Partner · 15 June 2026Partnership for development and distribution of Obagi saypha ChIQ injectable hyaluronic acid gel filler approved by FDA for cheek augmentation and midface contour correction. Product utilizes Croma's proprietary MACRO Core Technology, expanding Obagi's injectable portfolio in the US market.
  • MedfilecoreTechnology or Integration · 26 May 2026Strategic joint venture to accelerate Clinicore platform development. Partnership integrates AI-driven features including automated treatment documentation and intelligent onboarding tools into Croma's premium digital SaaS platform for aesthetic clinics.
  • ProMD HealthcoreGTM or Marketing Partner · 19 March 2026ALOHA Program collaboration to conduct real-world clinical evaluation of Obagi saypha MagIQ hyaluronic acid dermal filler across ProMD's 17 multi-state practice locations, collecting standardized data on clinical efficacy and patient experience.
  • Schweiger DermatologycoreGTM or Marketing Partner · 27 February 2026ALOHA Program key partner to conduct Phase 4 clinical study and real-world evaluation of Obagi saypha MagIQ injectable product across Schweiger's national network of practices, with initial activities beginning early 2026.
  • It's a Secret Med SpacoreGTM or Marketing Partner · 25 February 2026ALOHA Program collaboration to evaluate Obagi saypha MagIQ across 15 med spa locations using structured data capture and clinical protocols, translating FDA pivotal trial data into everyday premium med spa practice.
  • Aesthetic RecordcoreGTM or Marketing Partner · 17 February 2026ALOHA Program partnership leveraging Aesthetic Record's EMR, charting, and analytics platform across network of over 9,000 aesthetic clinics to generate real-world evidence for Obagi saypha MagIQ injectable.
  • MoxiecoreGTM or Marketing Partner · 5 February 2026ALOHA Program strategic partner using software, coaching, and operational tools to collect standardized data on filler integration into scalable aesthetic workflows across Moxie's supported med spa network.
  • VIO Med SpacoreGTM or Marketing Partner · 30 January 2026ALOHA Program launch partner conducting real-world clinical evaluations of Obagi saypha MagIQ across VIO's national network of med spa locations, generating evidence on performance and patient outcomes.
  • Next HealthcoreGTM or Marketing Partner · 28 January 2026ALOHA Program partnership for structured multi-site assessment of Obagi saypha MagIQ filler across Next Health's wellness and longevity centers, leveraging integration of injectables with holistic protocols.
  • Novaestiq Corp.flagshipStrategic or Co-development Partner · 23 July 2025Novaestiq Corp. acquired by Waldencast plc as part of Croma's expansion strategy, including launch of Saypha injectables in US under Obagi Medical brand.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Croma Pharma competitors and assessment

Company assessment

Broad incumbents

  • AbbVie (Allergan Aesthetics): Owns the Juvéderm HA filler franchise and Botox—the global category leaders in aesthetic injectables. A large public incumbent whose scale and R&D budget dwarf Croma's; directly competes across Croma's core injectable categories.
  • SkinCeuticals (L'Oréal Dermatological Beauty): Medical-grade skincare brand owned by L'Oréal. Comparable to Croma Skincare's positioning at the intersection of clinical aesthetics and consumer skincare, and a benchmark for Croma's consumer channel ambitions.

Direct peers

  • Galderma: Global dermatology and aesthetics leader with the Restylane HA filler portfolio, Sculptra biostimulator, and Dysport (botulinum toxin). Most direct competitor to Croma's minimally invasive aesthetics portfolio, especially in HA fillers and skin boosters.
  • Teoxane: Swiss manufacturer of HA-based dermal fillers (Teosyal range) and skincare. A direct European HA-filler peer with a comparable private, specialty-manufacturer profile and overlapping target customer (aesthetic practitioners).
  • Merz Aesthetics: Private German company offering Belotero HA fillers, Xeomin botulinum toxin, and Ultherapy. Closest peer to Croma: a private, European-rooted, mid-sized aesthetics player competing across overlapping injectable categories.
  • Sinclair Pharma: European aesthetics company (acquired by Huadong Medicine) with Ellansé biostimulator and HA fillers. A close comparable in size and business model before acquisition—mid-sized European aesthetics player serving the same HCP customer base.
  • IBSA (Institut Biochimique SA): Swiss pharma company offering HA-based products (e.g., Profhilo bio-remodelling, Sinovial for joint care). Directly comparable to Croma across both aesthetic injectables and orthobiologics (overlapping with Synocrom).

Emerging players

  • Evolus: US aesthetics company focused on botulinum toxin (Jeuveau). A focused competitor in the same minimally invasive aesthetics category as Croma's botulinum toxin product.
  • Revance Therapeutics: US aesthetics company with the RHA Collection of HA fillers and Daxxify (long-acting botulinum toxin). Comparable as a focused injectable aesthetics specialist targeting similar HCP customers.

Regional players

  • Hugel (Hugel Aesthetics): Korean aesthetics and medical aesthetics player with botulinum toxin (Botulax) and HA fillers. Comparable product portfolio to Croma's, primarily serving APAC but increasingly expanding globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Croma Pharma social profiles

Digital presence

Croma Pharma compliance and trust

Trust signal

Compliance1 record

Croma Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Croma Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Croma Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Croma Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Croma Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Croma Pharma

What does Croma Pharma do?

Croma-Pharma manufactures and distributes a comprehensive minimally invasive aesthetics portfolio including hyaluronic acid (HA) dermal fillers, botulinum toxin, skin boosters, PDO threads, and autologous PRP/Fluid-PRF treatments, plus an MDR-certified orthobiologic (Synocrom) for knee osteoarthritis. The company sells its products primarily to healthcare professionals and aesthetic clinics through direct B2B sales and a dedicated webshop (cromapharma.shop), and operates the Clinicore AI-driven SaaS platform for aesthetic clinic management alongside a consumer skincare line.

Is Croma Pharma a public or private company?

Croma Pharma is a private company. It is classified as family owned and is currently operating.

When was Croma Pharma founded?

Croma Pharma was founded in 1976. It employs 501 to 1,000 people.

Where is Croma Pharma based?

Croma Pharma is headquartered in Leobendorf, Austria, in the Europe region.

How does Croma Pharma make money?

Five revenue lines are on record. Aesthetics Product Portfolio Sales are the primary driver. The others are skincare Consumer Products, orthobiologics/Medical Devices, clinicore SaaS Platform and licensing and Development Partnerships.

Who are Croma Pharma's main competitors?

Broad incumbents on record are AbbVie (Allergan Aesthetics) and SkinCeuticals (L'Oréal Dermatological Beauty). Direct peers are Galderma, Teoxane, Merz Aesthetics, Sinclair Pharma and IBSA (Institut Biochimique SA). Emerging players are Evolus and Revance Therapeutics. Hugel (Hugel Aesthetics) is listed as a regional player.

Does Croma Pharma have an API?

No public API is recorded for Croma Pharma.

What industry is Croma Pharma in?

Croma Pharma's product category is Medical Aesthetics (Hyaluronic Acid Injectables). Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales